The Gastric Cancer Drugs Market is estimated to grow at a CAGR of 10.1% over the forecast period of 2023-2028, to garner a market size equivalent to $4.2 billion by 2028. A rampant or unusual increase in the cells across the stomach/gastric part of the body results in the development of gastric cancer. Gastric Cancer often follows a slower trajectory than other forms of cancer, thereby, the disease reaches a malignant stage in senior age. Some of the common forms of gastric cancer which affect more than 90% of all gastric cancer cases are Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST) and Neuroendocrine Tumors. Predominant treatment for gastric cancer includes, but is not limited to, Programmed Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor (HER2) Antagonists and others. The substantial caseload in Asia-Pacific supplemented by extensive research in the oncology field would propel the market during the forecast period.

For More Queries About "Gastric Cancer Drugs Market" @ https://www.industryarc.com/support.php?id=17556

Gastric Cancer Drugs Market Drivers

High Prevalence of Gastric/Stomach Cancer Cases across Geographies:

The prevalence of gastric cancer has been termed as worrying and ranked fifth in the overall new cases categories of cancer in 2020. As per Globocan 2020, 5.6% of all cancer cases diagnosed were termed stomach/gastric cancer. Furthermore, the death ratio of this form of cancer is high which further drives the need for drugs and medications. As per the same source, nearly 10.7% of all cancer-related deaths took place due to gastric cancer. Lastly, the prevalence in Asia-Pacific has driven the demand for drugs, as numerous cases are registered in this particular region.

Considerable Investments in the Field of Oncology:

Investments across the oncology field have been growing rampantly. The clinical activity levels in 2021 were at an all-time high, with extensive research for developing targeted medicines or therapies with minimal to no side effects. Additionally, the ever-growing proportion of the geriatric population aids the market, as the diagnosis and prognosis of the disease are present in the senior group. As per NCBI, nearly 90% of cases occur in those above the age of 65.

Research and Product Launch

In October 2022, HER-2 or Human Epidermal Growth Factor Receptor (HER2) Antagonists-positive biliary tract cancer, second-line or third-line trastuzumab biosimilar plus FOLFOX exhibited promising activity with acceptable toxicity. In May 2021, Bold Therapeutics received Orphan Drug Designation (ODD) for Bold-100. Bold-100 is specifically targeted for gastric cancer treatment and is a first-in-class ruthenium-based small molecule therapeutics.

The Major Players in the Market

The Major Players in the Gastric Cancer Drugs Market include Sun Pharmaceuticals, Sanofi-Aventis, Celltrion, Eli Lily, Bayer AG, Novartis AG, F-Hoffman La Roche, Bristol-Myers Squibb Company, Ipsen and Pharma and Merck and Co.

To request for a quote, provide your details in the below link:

https://www.industryarc.com/reports/request-quote?id=17556

Media Contact:

Mr. Venkat Reddy

Sales Manager

Email: [email protected]

Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.